BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3585444)

  • 1. Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.
    Falkson G; Gelman RS; Tormey DC; Falkson CI; Wolter JM; Cummings FJ
    J Clin Oncol; 1987 Jun; 5(6):881-9. PubMed ID: 3585444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
    Falkson G; Holcroft C; Gelman RS; Tormey DC; Wolter JM; Cummings FJ
    J Clin Oncol; 1995 Jun; 13(6):1453-8. PubMed ID: 7751892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
    Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
    J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Falkson G; Gelman RS; Tormey DC; Cummings FJ; Carbone PP; Falkson HC
    Cancer; 1985 Jul; 56(2):219-24. PubMed ID: 3839157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.
    Sparano JA; Wadler S; Liebes L; Robert NJ; Schwartz EL; Dutcher JP
    Cancer Res; 1993 Aug; 53(15):3509-12. PubMed ID: 8339255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081.
    Perry MC; Kardinal CG; Korzun AH; Ginsberg SJ; Raich PC; Holland JF; Ellison RR; Kopel S; Schilling A; Aisner J
    J Clin Oncol; 1987 Oct; 5(10):1534-45. PubMed ID: 3655856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.
    Stewart DJ; Evans WK; Shepherd FA; Wilson KS; Pritchard KI; Trudeau ME; Wilson JJ; Martz K
    J Clin Oncol; 1997 May; 15(5):1897-905. PubMed ID: 9164200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
    Cummings FJ; Gelman R; Horton J
    J Clin Oncol; 1985 Jul; 3(7):932-40. PubMed ID: 3894587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies.
    Falkson G; Gelman RS; Leone L; Falkson CI
    Cancer; 1990 Oct; 66(7):1621-9. PubMed ID: 2208013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
    Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study.
    Kardinal CG; Perry MC; Weinberg V; Wood W; Ginsberg S; Raju RN
    Breast Cancer Res Treat; 1983; 3(4):365-71. PubMed ID: 6365209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
    Pandya KJ; Hu P; Osborne CK; Falkson G; Tormey DC;
    Am J Clin Oncol; 2007 Apr; 30(2):113-25. PubMed ID: 17414459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.
    Ayoub J; Audet-Lapointe P; Méthot Y; Hanley J; Beaulieu R; Chemaly R; Cormier A; Déry JP; Drouin P; Gauthier P
    Gynecol Oncol; 1988 Oct; 31(2):327-37. PubMed ID: 2971597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Abeloff MD; Roseman DL; Gilchrist KW; Barylak EJ; Stott P; Falkson G
    J Clin Oncol; 1992 Dec; 10(12):1848-56. PubMed ID: 1453199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancer.
    Falkson CI; Falkson HC; Falkson G
    Ann Oncol; 1992 Dec; 3(10):849-53. PubMed ID: 1286048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.
    Falkson CI; Falkson G; Falkson CB; Falkson HC
    Oncology; 1992; 49(6):418-21. PubMed ID: 1465278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.